A phase 2 study showed that giving maintenance regorafenib could delay disease progression in patients with non-adipocytic ...

and Bayer is starting proceedings by opening enrolment for US patients in an arm evaluating its cancer drug regorafenib. Sponsored by the non-profit charitable organisation the Global Coalition ...